BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

In a resounding vote of confidence in China's biotechnology sector, leading global pharmaceutical companies are striking ...

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced. Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Read about 3SBio Inc Shs Unitary 144A/Reg S (TRSBF:PINX) stock and today's latest news and financial updates.

Last month, Pfizer joined the fray by licensing rights to 3SBio's SSGJ-707 in a $6 billion deal, while MSD penned its own near-$3.3 billion deal last year to get rights to LaNova Medicines' LM-299.

Get detailed information on the HS SCHK Healthcare including charts, technical analysis, components and more.

Currently, Alphamab trades at a price-to-earnings (P/E) ratio of 44 times, even higher than the 30 times for Henlius Biotech ...